For example, various human cancer types (such as bladder, breast, cervical, colon, lung, and ovarian cancer among others) show high expression of STn antigen, which is rare in normal human tissues (Karlen, P. Multiple aberrant glycosylation forms have been described in human cancers, identifying specific glycans as a class of cell surface molecules suitable for specific tumor targeting (Cheever, M. Furthermore, the non-human immunogenic sialic acid, N-glycolylneuraminic acid (Neu5Gc), seems to be differentially expressed on carcinomas such as breast cancer in the form of Neu5Gc-STn (GcSTn). With few exceptions, Tn and STn are not expressed in normal, healthy tissues. It has been estimated that about 80% of all carcinomas express the truncated glycans, the Tn Antigen and the sialylated form, Sialyl Tn (STn). BACKGROUND OF THE INVENTIONĪberrant glycosylation accompanies some of the other mutations commonly observed in carcinomas. This invention relates to methods for the development of compounds and compositions, including, but not limited to antibodies for the detection and/or removal of glycosylated matter from an organism. This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The United States government may have certain rights in the invention. HHSN261201400027C awarded by the Department of Health and Human Services. This invention was made with government support under Grant No.

1, 2015, the contents of each of which are herein incorporated by reference in their entirety. 15/526,593, filed May 12, 2017, which is a national stage of International Application No. 14, 2020, which is a continuation of U.S. This application is a continuation of U.S.

Flowjo serial number generator 7.6.5